Association of clinical signs and symptoms with pneumococcal acute otitis media by serotype--implications for vaccine effect.

BACKGROUND Clinical symptoms and signs in acute otitis media (AOM) may differ depending on the various pneumococcal serotypes causing the disease. Alteration in clinical presentation of AOM could be expected after wide-scale pneumococcal vaccinations if there were considerable differences between vaccine serotypes and nonvaccine serotypes. METHODS In this study, data from 831 children in the control arm of the Finnish Otitis Media Vaccine Trial were used. The children were followed up prospectively in 8 study clinics from 2 to 24 months of age. If AOM was diagnosed, myringotomy was done, and middle ear fluid was aspirated for bacterial culture. Clinical symptoms and signs of AOM were routinely recorded on structured case report forms. RESULTS Consistent with previous studies, 60% of pneumococcal episodes were caused by vaccine serotypes. There were no major differences between the clinical presentations of AOM due to different serotypes or serotype categories. However, earache was more often associated with AOM caused by vaccine and cross-reactive serotypes, compared with AOM caused by non-vaccine-related serotypes (42% vs. 29%; odds ratio, 1.66; 95% confidence interval, 1.02-2.70). CONCLUSIONS Introduction of the currently available pneumococcal conjugate vaccine is unlikely to result in a remarkable alteration in the clinical presentation of pneumococcal AOM in infants.

[1]  P. Mäkelä,et al.  Association of clinical signs and symptoms with bacterial findings in acute otitis media. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  M. Leinonen,et al.  Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  G. Yothers,et al.  Multinational study of pneumococcal serotypes causing acute otitis media in children , 2002, The Pediatric infectious disease journal.

[4]  A. Takala,et al.  Nasopharyngeal carriage of Streptococcus pneumoniae in Finnish children younger than 2 years old. , 2001, The Journal of infectious diseases.

[5]  A. Takala,et al.  Bacteriology of acute otitis media in a cohort of Finnish children followed for the first two years of life , 2001, The Pediatric infectious disease journal.

[6]  S. Lockhart,et al.  Efficacy of a pneumococcal conjugate vaccine against acute otitis media. , 2001, The New England journal of medicine.

[7]  Cynthia G. Whitney,et al.  Preventing pneumococcal disease among infants and young children : recommendations of the Advisory Committee on Immunization Practices (ACIP) , 2000 .

[8]  P W Smith,et al.  Association models for a multivariate binary response. , 2000, Biometrics.

[9]  S. Dowell,et al.  Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis , 2000, Pediatrics.

[10]  N. Bean,et al.  Surveillance for foodborne-disease outbreaks--United States, 1993-1997. , 2000, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[11]  E. Lewis,et al.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children , 2000, The Pediatric infectious disease journal.

[12]  G. Siber,et al.  The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  J. Koplan Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2000, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[14]  S. Obaro,et al.  Carriage of pneumococci after pneumococcal vaccination , 1996, The Lancet.